Reproductive Health Research
Melanocortin receptor pharmacology and sexual behaviour in preclinical models
What Is This Category?
PT-141, known clinically as Bremelanotide and sold as Vyleesi®, is the only FDA-approved peptide specifically for sexual dysfunction — approved in 2019 for hypoactive sexual desire disorder in premenopausal women. What makes PT-141 unique is where it acts: not in the blood vessels, like Viagra or Cialis, but in the brain. It activates melanocortin receptors in the hypothalamus — a region involved in desire, arousal, and motivation — producing an increase in sexual interest that is centrally driven rather than mechanically facilitated. This makes it relevant for addressing the desire and psychological components of sexual dysfunction, which PDE5 inhibitors cannot reach. It has been studied in both men and women, giving it one of the broadest clinical research bases of any peptide on this site.
What People Research This For
- →Research into sexual desire and central arousal pathways in both sexes
- →Studying the CNS (brain-driven) vs. vascular component of sexual response
- →Female sexual interest and arousal disorder (FSIAD) research
- →Erectile dysfunction research where psychological desire component is primary
- →Melanocortin receptor pharmacology and selectivity studies
Pros & Cons
Effects Timeline
Based on published study timelines. Human extrapolation is approximate — individual results vary.
Phase III clinical trial data shows measurable improvement in satisfying sexual events and desire scores within the 24-hour period following a single dose. Animal model effects (intromission latency, lordosis quotient) are measurable within 45–60 minutes of administration.
Scientific Overview
PT-141 (Bremelanotide) is a synthetic melanocortin receptor agonist derived from Melanotan II, developed for the study of central sexual arousal pathways. Unlike PDE5 inhibitors (sildenafil) that act peripherally on smooth muscle, PT-141 acts centrally via MC3R and MC4R receptors in the hypothalamus and limbic system to modulate dopaminergic reward circuits associated with sexual motivation and arousal. It has completed Phase II and III clinical trials and received FDA approval (Vyleesi) for hypoactive sexual desire disorder in premenopausal women, providing an unusually robust clinical dataset to complement preclinical research.
Mechanism of Action
PT-141 is a cyclic heptapeptide that selectively binds MC3R and MC4R in the central nervous system. MC4R activation in the medial hypothalamus and nucleus accumbens drives dopamine release in the mesolimbic pathway, modulating sexual motivation and erection/lubrication response in a CNS-dependent manner. Unlike MC1R (skin pigmentation) agonism associated with Melanotan II, PT-141's selectivity profile avoids significant pigmentation effects at therapeutic doses.
Administration Methods
Reconstitute lyophilised PT-141 in sterile saline to 1–2 mg/mL. The approved clinical formulation (Vyleesi) is pre-filled at 1.75 mg/0.3 mL.
1–2 mg/mL
SC injection produces peak plasma concentration within 60 min. Abdominal SC is used in both clinical and preclinical studies.
Dissolve in sterile saline at 1 mg/mL. Use calibrated nasal atomiser.
1 mg/mL
Intranasal formulation was used in early Phase I/II trials. The approved formulation is SC injection. Intranasal has lower and more variable bioavailability.
Research Protocols
Ki/EC50 at MC1R, MC3R, MC4R (radioligand competition binding); cAMP accumulation (HTRF assay); β-arrestin recruitment (BRET assay)
Intromission latency, mount frequency, lordosis quotient (female rats), erection latency (male rats), dopamine microdialysis in nucleus accumbens
Key Published Studies
PT-141: a melanocortin agonist for the treatment of sexual dysfunction
2004PT-141 induced penile erection in conscious rats via central MC3R/MC4R activation, without cardiovascular effects associated with PDE5 inhibitors, confirming its central (vs. peripheral) mechanism of action.
Bremelanotide (PT-141) in premenopausal women with hypoactive sexual desire disorder
2019Bremelanotide 1.75 mg SC significantly increased satisfying sexual events and reduced distress associated with low sexual desire vs. placebo in a Phase III randomised controlled trial.
Expected Outcomes
Based on the weight of published preclinical evidence. Outcomes may vary depending on model, dose, and administration route.
- ✓Selective MC3R/MC4R agonism with high MC1R selectivity ratio (receptor binding assays)
- ✓Reduced intromission latency and increased mount frequency in rodent sexual behaviour models
- ✓Increased lordosis quotient in hormone-primed ovariectomised female rats
- ✓Dopamine release in nucleus accumbens (microdialysis)
- ✓Minimal effect on blood pressure or heart rate at standard research doses
Safety Considerations
- ⚠PT-141 can cause transient nausea and flushing; these were the primary adverse events in clinical trials.
- ⚠Avoid in animals with pre-existing cardiovascular conditions; melanocortin receptor activation has modulatory effects on blood pressure.
- ⚠Pigmentation changes (MC1R activation) may occur at high doses; include skin monitoring in chronic dosing studies.
- ⚠Canadian availability is very limited; verify vendor stock and purity documentation before ordering.
Frequently Asked Questions
How does PT-141 differ from Melanotan II?
Melanotan II is a non-selective melanocortin agonist that activates all five MCR subtypes, including MC1R (tanning) and MC2R (cortisol). PT-141 is a structural analogue engineered for greater MC3R/MC4R selectivity, reducing pigmentation side-effects and the potent nausea associated with Melanotan II at comparable doses.
Is PT-141 approved as a drug?
Yes. Bremelanotide (PT-141) was FDA-approved in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not approved by Health Canada and Canadian availability for research purposes is limited.
Practical Notes for Self-Researchers
How does PT-141 compare to Viagra or Cialis for men?
PDE5 inhibitors (Viagra, Cialis) work by increasing blood flow to the penis — they address the physical mechanics of erection but cannot improve sexual desire. PT-141 works upstream in the brain, activating desire and arousal pathways through melanocortin receptors. For men whose primary issue is low desire or psychological arousal rather than vascular function, PT-141 addresses a component that PDE5 inhibitors cannot. The two have different — and potentially complementary — mechanisms.
How can I manage the nausea side effect?
Nausea is the primary dose-limiting side effect of PT-141. The Phase III trial protocol allowed participants to use 8 mg ondansetron (Zofran) as a pre-treatment 30 minutes before PT-141 injection — this significantly reduced nausea incidence. Starting with the lowest effective dose and injecting in the evening (when nausea can be slept through if it occurs) are practical approaches reported in the self-research community. Taking the injection on an empty stomach vs. with food does not consistently affect nausea in published data.
Source Peptides for Your Research
Compare Canadian peptide vendors on purity, testing, domestic warehouse availability, and price per mg.